Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTK2 | Q05397 | 1/20 | 0.43 |
| ▸ | SYK | P43405 | 1/20 | 0.42 |
| ▸ | TNK2 | Q07912 | 2/20 | 0.42 |
| ▸ | BTK | Q06187 | 3/20 | 0.42 |
| ▸ | WEE1 | P30291 | 6/20 | 0.41 |
| ▸ | ULK1 | O75385 | 3/20 | 0.40 |
| ▸ | ULK2 | Q8IYT8 | 3/20 | 0.40 |
| ▸ | PLK1 | P53350 | 1/20 | 0.40 |
| ▸ | AXL | P30530 | 2/20 | 0.39 |
| ▸ | JAK3 | P52333 | 1/20 | 0.39 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.39 |
| ▸ | CSF1R | P07333 | 1/20 | 0.39 |
| ▸ | KIT | P10721 | 1/20 | 0.39 |
| ▸ | SRC | P12931 | 1/20 | 0.39 |
| ▸ | FLT3 | P36888 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1284285 | 0.87 | CDK4 (0.51) | JAK3CSF1RSRC | |
| SCHEMBL1284832 | 0.86 | JAK3 (0.38) | WEE1PLK1JAK3SRC | |
| SCHEMBL1285557 | 0.85 | STAT6 (0.48) | PTK2JAK3CSF1R | |
| SCHEMBL1285097 | 0.84 | JAK2 (0.38) | WEE1PLK1JAK3SRC | |
| SCHEMBL1285380 | 0.84 | JAK3 (0.47) | SYKBTKWEE1JAK3SRC | |
| SCHEMBL1284954 | 0.83 | SYK (0.42) | SYKJAK3 | |
| SCHEMBL1284495 | 0.83 | JAK2 (0.38) | WEE1PLK1JAK3SRC | |
| SCHEMBL1284762 | 0.83 | SYK (0.41) | SYKJAK3 | |
| SCHEMBL1284702 | 0.82 | SYK (0.42) | SYKULK1PLK1JAK3NTRK1 | |
| SCHEMBL1284416 | 0.82 | JAK3 (0.49) | SYKJAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120088753-A1 | PYRROLOPYRIMIDINES AND USED AS KINASE INHIBITORS | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2012-04-12 | — | — | US | claimed |
| EP-2403853-A1 | PYRROLOPYRIMIDINES USED AS KINASE INHIBITORS | Medical Research Council Technology (GB) | 2012-01-11 | — | — | EP | claimed |
| US-20120088753-A1 | PYRROLOPYRIMIDINES AND USED AS KINASE INHIBITORS | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2012-04-12 | — | — | US | disclosed |
| EP-2403853-A1 | PYRROLOPYRIMIDINES USED AS KINASE INHIBITORS | Medical Research Council Technology (GB) | 2012-01-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088753-A1 | PYRROLOPYRIMIDINES AND USED AS KINASE INHIBITORS | MARK3, MAPK8, CDK8 | PTK2 183/4885SYK 230/4885TNK2 393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.